Loading BCRX detail
Loading ticker data...
Loading BCRX detail
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines.
The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika.
The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Chart data unavailable
— Experienced R&D leader with a track record of advancing innovative therapies from early development to global approval —
BioCryst Pharmaceuticals (NASDAQ: BCRX - Get Free Report) and Polydex Pharmaceuticals (OTCMKTS:POLXF - Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations and institutional ownership. Analyst Ratings This is a summary of recent
RESEARCH TRIANGLE PARK, N.C., April 03, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted 12 newly-hired employees stock options to purchase an aggregate of 33,950 shares, and restricted stock units (RSUs) covering an aggregate of 123,350 shares, of BioCryst common stock. The options and RSUs were granted as of April 1, 2026, as inducements material to each employee entering into employment with BioCryst. The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
Assenagon Asset Management S.A. trimmed its position in BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) by 88.4% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 359,580 shares of the biotechnology company's stock after selling 2,733,012 shares during the period. Assenagon
JPMorgan Chase and Co. lowered its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) by 28.5% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,132,377 shares of the biotechnology company's stock after selling 451,829 shares during the period.
Alkeon Capital Management LLC decreased its position in BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) by 4.4% during the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 5,464,021 shares of the biotechnology company's stock after selling 250,000 shares during the quarter. Alkeon Capital Management LLC owned
Avoro Capital Advisors LLC reduced its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) by 72.2% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,250,000 shares of the biotechnology company's stock after selling 3,250,000 shares during the period.
RESEARCH TRIANGLE PARK, N.C., March 04, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the compensation committee of BioCryst's board of directors granted six newly-hired employees restricted stock units (RSUs) covering an aggregate of 65,850 shares of BioCryst common stock. The RSUs were granted as of March 2, 2026, as inducements material to each employee entering into employment with BioCryst. The RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX - Get Free Report) have been given an average recommendation of "Moderate Buy" by the thirteen analysts that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have issued a buy rating
BioCryst Pharmaceuticals, Inc. (BCRX) Q4 2025 Earnings Call Transcript
BioCryst Pharmaceuticals (BCRX) came out with quarterly earnings of $1.12 per share, beating the Zacks Consensus Estimate of $0.07 per share. This compares to a loss of $0.13 per share a year ago.
—Full year 2025 ORLADEYO® net revenue of $601.8 million (+38% y-o-y; +43% y-o-y excluding European ORLADEYO revenue following the sale of the European ORLADEYO business to Neopharmed Gentili S.p.A. on October 1, 2025)—
BioCryst (BCRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GSA Capital Partners LLP lifted its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) by 70.7% in the undefined quarter, according to its most recent 13F filing with the SEC. The firm owned 190,294 shares of the biotechnology company's stock after purchasing an additional 78,827 shares during the quarter. GSA Capital Partners LLP owned
RESEARCH TRIANGLE PARK, N.C., Feb. 17, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the T.D. Cowen 46th Annual Health Care Conference in Boston on Tuesday, March 3, 2026, at 9:10 a.m. ET.
